VERRICA PHARMACEUTICALS ANNOUNCES COMPLETION OF ENROLLMENT IN FIRST PIVOTAL PHASE 3 TRIAL (COVE-2) EVALUATING YCANTH® FOR THE TREATMENT OF COMMON WARTS, WITH TOPLINE DATA EXPECTED Q1 2027

Reuters · 3d ago

Please log in to view news